← Back to Home

Despite agreement on Phase 3 trial design, Caribou plans to halt two allogeneic CAR-T programs amid financing pressure

Moving from early efficacy signals to large-scale confirmatory trials requires cell therapies to clear a funding hurdle. Caribou plans to end development of vispa-cel and CB-011, substantially reduce its workforce, and seek a merger or asset transaction; patients already treated remain in long-term follow-up studies.

By SURL BioNews

Even a therapy preparing to enter a pivotal trial can stall when funding is difficult to secure. On October 6, 2026, US biotech company Caribou Biosciences announced plans to discontinue further development of its two allogeneic CAR-T cell therapies, vispa-cel and CB-011, and substantially reduce its workforce. The company attributed the decision to the financing environment: raising sufficient capital to continue advancing research has become increasingly difficult.

The decision particularly highlights the gap between clinical progress and financial conditions. According to Caribou, the company has reached agreement with the US Food and Drug Administration (FDA) on the Phase 3 trial design for vispa-cel in relapsed or refractory B-cell non-Hodgkin lymphoma. Agreement on a trial design, however, does not mean that efficacy has been confirmed or that the drug has been approved for marketing; further funding is still needed to complete larger-scale validation.

The two programs each seek to address biological challenges in allogeneic cell therapy. vispa-cel targets CD19 and uses gene editing to knock out PD-1, with the aim of reducing premature T-cell exhaustion. CB-011, intended for relapsed or refractory multiple myeloma, targets BCMA and uses an immune-cloaking design to try to reduce rejection of the therapeutic cells by the patient's immune system. These designs provide directions for research, but whether they can translate into durable clinical benefits still depends on trial evidence.

In its summary of previously announced Phase 1 results, BioPharm International reported overall response rates of 82% and 86% in two vispa-cel patient cohorts, respectively, and 92% for CB-011. These figures indicate early antitumor activity, but patient characteristics and follow-up durations may differ across trials, so the results cannot be compared directly. Response rates alone also cannot establish survival benefits or long-term safety. The reason given for halting development in this announcement was financing difficulties; no new findings of efficacy failure were announced.

Specific wind-down arrangements are already in place. Caribou's 8-K filing shows that its board approved the restructuring on October 2, with estimated costs of $15 million to $19 million. Of that amount, $10 million to $11 million relates to severance and associated expenses, while another $5 million to $8 million will be used to close the two Phase 1 trials, ANTLER and CaMMouflage. Most affected employees are expected to leave in the fourth quarter, while a small number will remain to assist with potential transactions and the wind-down of operations; the company did not disclose the percentage of its workforce being cut.

Halting further development also leaves existing research responsibilities and operational arrangements to address. The filing states that patients previously treated with the company's investigational therapies remain enrolled in ongoing long-term follow-up studies. The company will also address contracts and intellectual property licensing arrangements, and seek to sublease its facilities or terminate leases. Some related expenses cannot yet be estimated, so the restructuring costs currently announced may still change.

The options Caribou is evaluating include mergers, acquisitions, and other transactions involving the company or its assets, and it has retained Wedbush Securities as its financial adviser. However, there is no timeline for completing the review and no guarantee that it will result in a transaction. This event illustrates a practical hurdle for off-the-shelf cell therapies moving toward clinical use: early research can offer hope, and regulatory discussions can clarify the path, but completing pivotal validation still requires sustained financial support.

References

  1. Caribou Biosciences / SEC
  2. Caribou Biosciences / U.S. Securities and Exchange Commission
  3. BioPharm International